Cases & Deals

  • Home
  • Practices
  • Ysios Capital and strategic investor invest in Kala Pharmaceuticals

Share

Ysios Capital and strategic investor invest in Kala Pharmaceuticals

April 2014

Client(s) Ysios Capital Partners and strategic investor

Jones Day represented Ysios Capital Partners and a strategic investor in connection with their investment in a $22.5 million private placement of Series B Preferred Stock by Kala Pharmaceuticals, Inc., a leading developer of innovative products that enhance penetration of therapeutic agents into ocular tissue based on Kala’s proprietary Mucus Penetrating Particle technology.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.